KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBT Margin (2016 - 2025)

Acadia Pharmaceuticals has reported EBT Margin over the past 16 years, most recently at 9.27% for Q4 2025.

  • Quarterly results put EBT Margin at 9.27% for Q4 2025, down 5278.0% from a year ago — trailing twelve months through Dec 2025 was 12.96% (down 1398.0% YoY), and the annual figure for FY2025 was 12.96%, down 1398.0%.
  • EBT Margin for Q4 2025 was 9.27% at Acadia Pharmaceuticals, down from 16.01% in the prior quarter.
  • Over the last five years, EBT Margin for ACAD hit a ceiling of 62.05% in Q4 2024 and a floor of 97.49% in Q1 2022.
  • Median EBT Margin over the past 5 years was 3.71% (2023), compared with a mean of 10.16%.
  • Biggest five-year swings in EBT Margin: skyrocketed 5956bps in 2023 and later plummeted -5278bps in 2025.
  • Acadia Pharmaceuticals' EBT Margin stood at 32.81% in 2021, then increased by 9bps to 29.92% in 2022, then soared by 157bps to 17.17% in 2023, then soared by 261bps to 62.05% in 2024, then crashed by -85bps to 9.27% in 2025.
  • The last three reported values for EBT Margin were 9.27% (Q4 2025), 16.01% (Q3 2025), and 15.19% (Q2 2025) per Business Quant data.